A5010933908- RNA Interference and Gene Delivery
- Nanoparticle-Based Drug Delivery
- Monoclonal and Polyclonal Antibodies Research
- Dendrimers and Hyperbranched Polymers
- Radiopharmaceutical Chemistry and Applications
- Advanced biosensing and bioanalysis techniques
- Chemical Synthesis and Analysis
- Peptidase Inhibition and Analysis
- Metal complexes synthesis and properties
- HER2/EGFR in Cancer Research
- Cell Adhesion Molecules Research
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Click Chemistry and Applications
- Glycosylation and Glycoproteins Research
- Chronic Lymphocytic Leukemia Research
- Nanoplatforms for cancer theranostics
- Prostate Cancer Treatment and Research
Cancer Targeted Technology (United States)
2025
Washington State University
2021-2024
We present PD-CTT1298 nanoplatform as a versatile approach for selective systemic delivery of high payloads potent chemotherapeutics to PSMA (+) prostate cancer, where dose related side-effects are major concern.
Monomethyl auristatin E (MMAE) is a promising treatment option for patients diagnosed with prostate cancer (PCa); however, toxicities prevent MMAE from being administered as free drug. No MMAE-based currently marketed PCa. Herein, we describe small-molecule-drug conjugate, CTT2274, the selective delivery of MMAE. CTT2274 composed prostate-specific membrane antigen (PSMA)-binding scaffold, biphenyl motif, pH-sensitive phosphoramidate linker, and payload. We demonstrate that shows binding to...
Prostate cancer (PC) is the fifth leading cause of cancer-related deaths among men worldwide. Prostate-specific membrane antigen (PSMA), a molecular target PC, clinically used for treatment and diagnosis PC using radioligand approaches. However, no PSMA-based chemotherapies have yet been approved by FDA. Here, we present novel therapeutic approach PSMA-targeted 2-deoxyglucose-dendrimer (PSMA-2DG-D) targeted delivery potent tyrosine kinase inhibitor, cabozantinib (Cabo), selectively to cells....
The tunable nature of phosphoramidate linkers enables broad applicability as pH-triggered controlled-release platforms, particularly in the context antibody- and small-molecule-drug conjugates (ADCs SMDCs), where there remains a need for new linker technology. Herein, we explored in-depth release turn-on fluorogenic payloads from homoserinyl-based acid-cleavable linker. Kinetics payload scaffold was observed buffers representing pH conditions systemic circulation, early late endosomes,...
In this study, we present a modular synthesis and evaluation of two prostate-specific membrane antigen (PSMA) targeted small molecule drug conjugates (SMDCs) incorporating the potent chemotherapeutic agent monomethyl auristatin E (MMAE). These SMDCs are distinguished by their cleavable linker modules: one utilizing widely known valine-citrulline linker, susceptible to cleavage cathepsin B, other featuring novel acid-labile phosphoramidate-based (PhosAm) linker. Both maintained nanomolar...
Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI
Herein, we report the modular synthesis and evaluation of a prostate-specific membrane antigen (PSMA) targeted small molecule drug conjugate (SMDC) carrying chemotherapeutic agent, SN38. Due to fluorogenic properties SN38, payload release kinetics from platform was observed in buffers representing pH conditions systemic circulation cellular internalization. It found that this is stable with minimal at physiological most rapid values endosome complex. We confirmed selective efficacy for...